Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis

Hormone and Metabolic Research

Volumn 47, Issue 9, 2015, Pages 686-692

  Ojima, A ^a   Matsui, T ^a   Nishino, Y ^a   Nakamura, N ^a   Yamagishi, S ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AGEs; diabetic nephropathy; oxidative stress; RAGE; SGLT2

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; EMPAGLIFLOZIN; FATTY ACID BINDING PROTEIN; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GENE EXPRESSION; HYPERGLYCEMIA; MACROPHAGE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; URINARY EXCRETION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; FIBROMYALGIA; INFLAMMATION; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBROMYALGIA; GENE EXPRESSION; GLUCOSIDES; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPOGLYCEMIC AGENTS; INFLAMMATION; MALE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84930214161     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0034-1395609     Document Type: Article

References (36)

1. Yamagishi S., Fukami K., Ueda S., Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets: 2007; 8 952 959
2. Karnib H. H., Ziyadeh F. N. The cardiorenal syndrome in diabetes mellitus. Diabetes Res Clin Pract: 2010; 89 201 208
3. Alsaad K. O., Herzenberg A. M. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol: 2007; 60 18 26
4. Taft J. L., Nolan C. J., Yeung S. P., Hewitson T. D., Martin F. I. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes: 1994; 43 1046 1051
5. Ziyadeh F. N., Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int: 1991; 39 464 475
6. Vlassara H., Bucala R. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes: 1996; 03 S65 S66
7. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med: 1988; 318 1315 1321
8. Rahbar S. Novel inhibitors of glycation and AGE formation. Cell Biochem Biophys: 2007; 48 147 157
9. Yamamoto Y., Kato I., Doi T., Yonekura H., Ohashi S., Takeuchi M., Watanabe T., Yamagishi S., Sakurai S., Takasawa S., Okamoto H., Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest: 2001; 108 261 268
10. Wendt T. M., Tanji N., Guo J., Kislinger T. R., Qu W., Lu Y., Bucciarelli L. G., Rong L. L., Moser B., Markowitz G. S., Stein G., Bierhaus A., Liliensiek B., Arnold B., Nawroth P. P., Stern D. M., D'Agati V. D., Schmidt A. M. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol: 2003; 162 1123 1137
11. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des: 2005; 11 2279 2299
12. Yamagishi S., Nakamura K., Matsui T., Noda Y., Imaizumi T. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des: 2008; 14 487 495
13. Forbes J. M., Cooper M. E. Glycation in diabetic nephropathy. Amino Acids: 2012; 42 1185 1192
14. Ojima A., Ishibashi Y., Matsui T., Maeda S., Nishino Y., Takeuchi M., Fukami K., Yamagishi S. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol: 2013; 182 132 141
15. Maeda S., Matsui T., Takeuchi M., Yoshida Y., Yamakawa R., Fukami K., Yamagishi S. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacol Res: 2011; 63 241 248
16. Matsui T., Yamagishi S., Takeuchi M., Ueda S., Fukami K., Okuda S. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun: 2010; 398 326 330
17. +/glucose cotransporters in renal proximal tubule cells. Kidney Int: 2007; 72 527 535
18. Sabolic I., Vrhovac I., Eror D. B., Gerasimova M., Rose M., Breljak D., Ljubojevic M., Brzica H., Sebastiani A., Thal S. C., Sauvant C., Kipp H., Vallon V., Koepsell H. Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol: 2012; 302 C1174 C1188
19. Santer R., Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol: 2010; 5 133 141
20. Bailey C. J., Gross J. L., Pieters A., Bastien A., List J. F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet: 2010; 375 2223 2233
21. Maeda S., Matsui T., Takeuchi M., Yamagishi S. Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes Metab Res Rev: 2013; 29 406 412
22. Takeuchi M., Makita Z., Bucala R., Suzuki T., Koike T., Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med: 2000; 6 114 125
23. Panchapakesan U., Pegg K., Gross S., Komala M. G., Mudaliar H., Forbes J., Pollock C., Mather A. Effects of SGLT2 inhibition in human kidney proximal tubular cells - renoprotection in diabetic nephropathy? PLoS One: 2013; 8 e54442
24. Osorio H., Coronel I., Arellano A., Pacheco U., Bautista R., Franco M., Escalante B. Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid Med Cell Longev. 2012; 542042
25. Morrisey K., Steadman R., Williams J. D., Phillips A. O. Renal proximal tubular cell fibronectin accumulation in response to glucose is polyol pathway dependent. Kidney Int: 1999; 55 160 167
26. Gilbert R. E. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? Kidney Int: 2014; 86 693 700
27. Vallon V., Rose M., Gerasimova M., Satriano J., Platt K. A., Koepsell H., Cunard R., Sharma K., Thomson S. C., Rieg T. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol: 2013; 304 F156 F167
28. Vallon V., Gerasimova M., Rose M. A., Masuda T., Satriano J., Mayoux E., Koepsell H., Thomson S. C., Rieg T. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol: 2014; 306 F194 F204
29. Matsui T., Yamagishi S., Takeuchi M., Ueda S., Fukami K., Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res: 2010; 61 34 39
30. Ishibashi Y., Matsui T., Takeuchi M., Yamagishi S. Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression. Horm Metab Res: 2012; 44 891 895
31. Chung A. C., Zhang H., Kong Y. Z., Tan J. J., Huang X. R., Kopp J. B., Lan H. Y. Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol: 2010; 21 249 260
32. Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Renal Physiol: 2011; 300 R1009 R1022
33. Albertoni Borghese M. F., Majowicz M. P., Ortiz M. C., Passalacqua Mdel R., Sterin Speziale N. B., Vidal N. A. Expression and activity of SGLT2 in diabetes induced by streptozotocin: relationship with the lipid environment. Nephron Physiol: 2009; 112 45 52
34. Osorio H., Coronel I., Arellano A., Franco M., Escalante B., Bautista R. Ursodeoxycholic acid decreases sodium-glucose cotransporter (SGLT2) expression and oxidative stress in the kidney of diabetic rats. Diabetes Res Clin Pract: 2012; 97 276 282
35. Abdul-Ghani YM A., DeFronzo R. A., Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes: 2013; 62 3324 3328
36. Powell D. R., DaCosta C. M., Gay J., Ding Z. M., Smith M., Greer J., Doree D., Jeter-Jones S., Mseeh F., Rodriguez L. A., Harris A., Buhring L., Platt K. A., Vogel P., Brommage R., Shadoan M. K., Sands A. T., Zambrowicz B. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab: 2013; 304 E117 E130